China Israel Value Capital (CIVC) and Shenzhen Capital Group Co., (SCGC) invested in Shanghai Celgen Biopharmaceutical co, Ltd ("Celgen"), a leading bio-similar biopharmaceuticals drugs developer and manufacture in China.

For the press release please click here.